000			04067nam a22003855i 4500
001			85272
003			ES-MaUEC
005			20230207040503.0
007			cr nn 008mamaa
008			160125s2016 gw | s |||| 0|eng d
020			_a9783319270166
040			_aES-MaUEC
050		4	_aRC271.C5 _b2016 EB
082	0	4	_a616.994
245	1	0	_aManagement of Chemotherapy-Induced Nausea and Vomiting : _bNew Agents and New Uses of Current Agents _cedited by Rudolph M Navari
250			_a1st ed.
260			_aCham _bSpringer International Publishing _bImprint _bAdis _c2016
300			_a1 recurso en línea (VIII, 181 páginas) _b17 ilustraciones, 9 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
520	3		_aThis book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients� perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_aFarmacología _0comprobar BNE19900953030 _2embne _9137893
700	1		_aNavari, Rudolph M. _eeditor literario _998110 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-27016-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319270166
907			_a.b1294550x _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC271.C5 M363 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11589383 _z06-04-17
999			_c85272 _d85272 _x1